

Cardiac Prosthetic Devices Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 400 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

Report description:

The global cardiac prosthetic devices market was valued at USD 7.15 Billion in 2024, driven by the increasing prevalence of cardiovascular disorders, rapid technological advancements, and growing demand for minimally invasive procedure across the globe. Innovations such as compact pacemakers and suture-less valve replacements are significantly propelling the market. It is expected to grow at a CAGR of 8.90% and attain a market value of USD 16.77 Billion by 2034. Rising healthcare investments, improved patient outcomes, and a focus on cutting-edge solutions further strengthen growth rate worldwide.

The global cardiac prosthetic devices market demand is driven by the rising prevalence of valve disorders, heart failure, and congenital heart defects. Increasing demand for advanced treatment options has driven innovations in artificial heart valves, enhancing patient outcomes. Advancements in biocompatible materials have improved durability and reduced complications, making these devices more effective. Additionally, mechanical circulatory support devices are gaining traction as crucial solutions for severe cardiac conditions. The growing adoption of artificial heart valves in minimally invasive procedures further boosts market expansion. Moreover, mechanical circulatory support devices play a vital role in maintaining cardiac function in patients with end-stage heart disease. The global market is expected to grow steadily due to rising healthcare investments, improved surgical techniques, and increasing awareness of advanced cardiac treatments. As the burden of cardiovascular diseases rises, the demand for innovative prosthetic solutions continues to drive market progress, ensuring better patient care worldwide.

The rising aging global population and increasing burden of cardiovascular diseases (CVDs) are key factors driving the demand for cardiac prosthetic devices. With a growing focus on improving cardiovascular health, advancements in medical technology have led to innovative solutions for managing heart conditions. Continuous progress in surgical techniques has enhanced the efficiency of implanting cardiac prosthetic devices, reducing recovery times and improving patient outcomes. The expansion of treatment options such as transcatheter heart valves has further strengthened market growth. Investments in research and development (R&D) are fostering next-generation prosthetic innovations, offering better biocompatibility and longevity. Additionally, the healthcare sector is increasingly adopting personalised solutions, ensuring improved patient-centric care. The rising incidence of cardiovascular diseases worldwide underscores the urgent need for technologically advanced prosthetic solutions. With ongoing advancements, the market is set to witness sustained growth, addressing the evolving demands of healthcare providers and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

patients alike.

Cardiac Prosthetic Devices Market Trends/Drivers

Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:

Rising Incidence of Cardiovascular Diseases and their Awareness Boosts Market Growth

The growing incidence of cardiovascular diseases, including coronary artery disease, heart failure, and valvular heart diseases, is significantly driving demand for cardiac prosthetic devices. With increasing awareness, early diagnosis and timely interventions are improving patient outcomes. Advancements in treatment options have led to innovations in cardiac prosthetics, enhancing durability and functionality. Additionally, advanced imaging techniques such as echocardiography and cardiac MRI are improving precision in diagnosing and treating complex cardiac conditions. Government initiatives, healthcare campaigns, and non-profit organisations are actively promoting heart health awareness, and encouraging regular screenings along with preventive measures. As the global burden of cardiovascular diseases continues to rise, the demand for technologically advanced and minimally invasive prosthetic solutions is increasing. These innovations are improving patient survival rates, reducing hospital stays, and enhancing the overall quality of life for individuals with severe heart conditions.

Surge in Favorable Reimbursement Policies to Augment Market Value

The increasing implementation of reimbursement policies is significantly driving the cardiac prosthetic devices market. Governments and private insurers worldwide are expanding healthcare coverage, reducing out-of-pocket expenses for patients requiring advanced cardiac treatments. Enhanced reimbursement frameworks improve the affordability of cardiac prosthetic devices, making them more accessible to a larger patient population. These policies encourage hospitals and clinics to adopt cutting-edge medical technology, further propelling market growth. Additionally, improved healthcare funding fosters innovation in cardiac prosthetic devices, ensuring better treatment outcomes. Strengthened healthcare infrastructure and supportive regulations also enhance accessibility, allowing more patients to benefit from life-saving cardiac interventions. As governments prioritise healthcare, the demand for cardiac prosthetic devices is expected to rise steadily. Expanding insurance coverage and favourable pricing strategies will continue to shape the market, ensuring broader adoption and increased patient access to advanced cardiac solutions.

Surge in Technological Innovations to Improve Cardiac Surgery Techniques and Devices

Advancements in cardiac surgical techniques are transforming patient care, with increasing adoption of minimally invasive procedures that reduce complications and recovery time. Cutting-edge robotic-assisted surgeries and transcatheter interventions are enhancing procedural accuracy and patient outcomes. The demand for durable cardiac prosthetic devices is rising, particularly for transcatheter heart valves, which improve success rates in valve replacement procedures. Additionally, innovations in ventricular assist devices (VADs) and pacemakers integrate wireless connectivity and remote monitoring, ensuring proactive patient management. Furthermore, advanced sensors optimise real-time data collection, enhancing diagnostics and device efficiency. As technology progresses, next-generation heart valves with superior biocompatibility and longevity are being developed. These innovations are reshaping the market, offering safer and more effective solutions for patients with cardiovascular conditions. Ongoing research and investments in cutting-edge technology will continue to drive market growth and improve cardiac care worldwide.

Global Cardiac Prosthetic Devices Industry Segmentation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This report provides an analysis of forecasts for revenue growth at the global, regional, and country levels, and the latest industry trends in each of the sub-segments from 2025 to 2034. For this study, Expert Market Research has segmented the global cardiac prosthetic devices market report based on product type, end-user, and region.

Market Breakup by Product Type

- Valves
 - ??- Tissue Valve
 - ??- Transcatheter Valve
 - ??- Mechanical Valve
 - ??- Others
- Pacemakers
 - ??- Implantable Pacemakers
 - ??- External Pacemaker
 - ??- Others

Market Breakup by End User

- Hospitals & Clinics
- Ambulatory Surgical Centers (ASCs)
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Valves dominate the market

The market for cardiac prosthetic devices is segmented by product type, including valves and pacemakers. Valves dominate the sector, encompassing mechanical valves, tissue valves, stented tissue valves, stentless tissue valves, and transcatheter valves. Their widespread adoption is due to enhanced durability and biocompatibility. Meanwhile, pacemakers, comprising implantable and external pacemakers, are gaining traction due to rising cardiovascular conditions. Implantable pacemakers include single-chamber, dual-chamber, and triple-chamber battery pacemakers, offering tailored cardiac rhythm management. Innovations in valves and pacemakers continue to drive industry growth, improving patient outcomes and treatment efficiency.

Advancements in valve design are enhancing durability and function, leading to broader adoption of valve products. The shift toward minimally invasive procedures is increasing demand for transcatheter heart valve replacement, particularly for high-risk patients. Improved materials and next-generation solutions are enhancing longevity and biocompatibility, reducing complications. Ongoing research is expected to drive further innovations in valve products worldwide.

Developments in medical technology are driving market growth, with innovative pacemaker devices integrating wireless

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

connectivity and remote monitoring capabilities. The rising prevalence of lifestyle-related diseases, including obesity, diabetes, and related heart ailments, is increasing demand for pacemakers. These advancements improve patient care by enabling real-time monitoring and early detection of complications, ensuring better clinical outcomes.

Hospitals, clinics and cardiac centers hold the largest share in the market

The market is segmented by end-user, including hospitals, clinics, cardiac centers, and ambulatory surgical centers. Hospitals, clinics, and cardiac centers dominate due to advanced medical facilities and skilled specialists. However, ambulatory surgical centers are gaining traction due to cost-effective, efficient treatments. Their ability to perform cardiac procedures with shorter recovery times contributes to increasing demand in the sector.

The rising adoption of innovative devices like artificial heart valves and implantable pacemakers in hospitals, clinics, and cardiac centers is enhancing cardiovascular care. Continuous advancements in medical technology and surgical techniques allow these facilities to provide cutting-edge treatment options. Moreover, government initiatives and healthcare reforms focus on improving patient outcomes, further driving demand. These factors make hospitals, clinics, and cardiac centers pivotal in expanding the market for cardiac prosthetic devices.

Ambulatory surgical centers (ASCs) play a crucial role in performing cardiac procedures, offering cost-effective and efficient solutions. With advancements in minimally invasive surgeries, ASCs provide safe outpatient treatments, reducing hospital stays. The shift towards value-based healthcare has increased patient preference for ASCs. Improved technology now enables complex cardiac procedures in these settings, further boosting market demand.

North America exhibits a clear dominance, accounting for the largest cardiac prosthetic devices market share

The global cardiac prosthetic devices market is expanding across key regional markets, including North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America leads due to advanced healthcare facilities and high adoption of cutting-edge technologies. Europe follows, benefiting from strong research initiatives and increasing cardiac surgeries. The Asia Pacific region is witnessing rapid growth due to rising healthcare investments and an expanding patient pool. Meanwhile, Latin America along with the Middle East and Africa are experiencing steady growth, driven by improving healthcare infrastructure and increasing awareness of cardiovascular health.

North America dominates the market due to the high prevalence of cardiovascular diseases and the rising demand for advanced heart valves, pacemakers, and implantable defibrillators. The region's robust healthcare system supports innovation, while strong reimbursement support ensures patient access to life-saving treatments. Additionally, significant research and development efforts drive the creation of innovative and minimally invasive prosthetic devices, improving patient outcomes. Increasing investments in medical technology and favourable regulatory frameworks further enhance market expansion. With ongoing advancements and a growing patient base, North America remains a key hub for cardiac prosthetic device development and adoption.

Asia Pacific is experiencing rapid growth due to its expanding aging population and changing lifestyles, which are increasing the prevalence of cardiovascular conditions. Improvements in healthcare infrastructure and rising disposable income have enhanced access to medical treatments, improving overall patient care. However, affordability remains a key concern, influencing market penetration. Ongoing technological advancements and innovations in cardiac prosthetic devices are further accelerating market expansion. As awareness and accessibility continue to rise, the Asia Pacific region is expected to play a crucial role in shaping the future of the global cardiac prosthetic devices market.

Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The market for cardiac prosthetic devices is becoming increasingly dynamic, driven by advancements in medical technology and evolving surgical procedures. Companies are investing heavily in research and development to create innovative devices that enhance patient outcomes. The integration of digital health technologies and remote monitoring solutions is transforming post-surgical care, enabling real-time health tracking. Furthermore, 3D printing technology is revolutionising the sector by facilitating the production of patient-specific devices, offering customizable solutions for improved compatibility. These advancements, along with personalized healthcare services, are shaping the future of cardiac prosthetics, ensuring efficient devices tailored to individual patient needs. Additionally, the growing focus on tailored solutions allows healthcare professionals to deliver more precise and effective treatments, improving overall cardiac care.

The competitive landscape of the market is characterised by continuous innovation and strategic growth initiatives. Key players are strengthening their market presence through collaborations, acquisitions, and product development, with an emphasis on data-driven analysis and technological advancements. Some of the key players in the market include:

- Abbott Laboratories
- LivaNova PLC
- Medtronic Plc
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- Colibri Heart Valve
- Meril Life Sciences Pvt Ltd
- BioTronik
- Lepu Medical Technology Co Ltd
- Siemens Healthineers
- Sorin Group
- St. Jude Medical Inc.

Recent Developments

In July 2024, Octagos Health secured USD 43 million in Series B funding, led by Morgan Stanley Expansion Capital. The investment will enhance its AI-driven platform for continuous monitoring of pacemakers, defibrillators, and wearable cardiac devices, improving real-time data analysis and remote patient management in advanced cardiac care.

In June 2024, Medtronic plc launched the AVALUS Ultra valve, a next-generation surgical aortic tissue valve designed for enhanced ease of implantation and lifetime patient management. This innovation aims to provide a durable and future-ready aortic valve solution for cardiac surgeons and patients. The AVALUS Ultra valve enhances surgical outcomes, supporting the growing demand for advanced cardiac prosthetic devices in valve replacement procedures.

In May 2024, the FDA approved the Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve System for replacing failing surgical biological mitral valves in patients at intermediate or high risk for open-heart surgery. The system, featuring a catheter-based artificial heart valve, was previously approved for treating aortic stenosis and failing surgical or transcatheter aortic and mitral valves in high-risk patients.

In February 2024, the FDA approved the Edwards EVOQUE Tricuspid Valve Replacement System, featuring a bioprosthetic tricuspid valve and delivery catheter. Made from cow tissue and a self-expanding metal frame, it enables minimally invasive valve replacement, preventing blood backflow into the right atrium without requiring open-heart surgery, and improving patient outcomes.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

A WHO/Europe report highlighted that hypertension is commonly caused by excessive salt consumption and affects around 1 in 3 adults (aged between 30-79) in the European Region. CVDs cause 42.5% of deaths annually, with men 2.5 times more likely to die than women. The report urges salt reduction and better hypertension control.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cardiac Prosthetic Devices Market Overview
 - 3.1 Global Cardiac Prosthetic Devices Market Historical Value (2018-2024)
 - 3.2 Global Cardiac Prosthetic Devices Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Global Cardiac Prosthetic Devices Market Landscape*
 - 5.1 Global Cardiac Prosthetic Devices Market: Developers Landscape
 - 5.1.1 Analysis by Year of Establishment
 - 5.1.2 Analysis by Company Size
 - 5.1.3 Analysis by Region
 - 5.2 Global Cardiac Prosthetic Devices Market: Product Landscape
 - 5.2.1 Analysis by Product Type
- 6 Global Cardiac Prosthetic Devices Market Dynamics
 - 6.1 Market Drivers and Constraints
 - 6.2 SWOT Analysis
 - 6.2.1 Strengths
 - 6.2.2 Weaknesses
 - 6.2.3 Opportunities
 - 6.2.4 Threats
 - 6.3 PESTEL Analysis
 - 6.3.1 Political
 - 6.3.2 Economic
 - 6.3.3 Social
 - 6.3.4 Technological
 - 6.3.5 Legal
 - 6.3.6 Environment
 - 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Cardiac Prosthetic Devices Market Segmentation (218-2034)
- 7.1 Global Cardiac Prosthetic Devices Market (2018-2034) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Valves
- 7.1.2.1 Tissue Valve
- 7.1.2.2 Transcatheter Valve
- 7.1.2.3 Mechanical Valve
- 7.1.2.4 Others
- 7.1.3 Pacemakers
- 7.1.3.1 Implantable Pacemakers
- 7.1.3.2 External Pacemakers
- 7.1.3.3 Others
- 7.2 Global Cardiac Prosthetic Devices Market (2018-2034) by End User
- 7.2.1 Market Overview
- 7.2.2 Hospitals & Clinics
- 7.2.3 Ambulatory Surgical Centers (ASCs)
- 7.2.4 Others
- 7.3 Global Cardiac Prosthetic Devices Market (2018-2034) by Region
- 7.3.1 Market Overview
- 7.3.2 North America
- 7.3.3 Europe
- 7.3.4 Asia Pacific
- 7.3.5 Latin America
- 7.3.6 Middle East and Africa
- 8 North America Cardiac Prosthetic Devices Market (218-2034)
- 8.1 North America Cardiac Prosthetic Devices Market (2018-2034) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Valves
- 8.1.2.1 Tissue Valve
- 8.1.2.2 Transcatheter Valve
- 8.1.2.3 Mechanical Valve
- 8.1.2.4 Others
- 8.1.3 Pacemakers
- 8.1.3.1 Implantable Pacemakers
- 8.1.3.2 External Pacemakers
- 8.1.3.3 Others
- 8.2 North America Cardiac Prosthetic Devices Market (2018-2034) by End User
- 8.2.1 Market Overview
- 8.2.2 Hospitals & Clinics
- 8.2.3 Ambulatory Surgical Centers (ASCs)
- 8.2.4 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3 North America Cardiac Prosthetic Devices Market (2018-2034) by Country
 - 8.3.1 United States of America
 - 8.3.1.1 United States of America Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 8.3.2 Canada
 - 8.3.2.1 Canada Cardiac Prosthetic Devices Market (2018-2034) by Product Type
- 9 Europe Cardiac Prosthetic Devices Market (218-2034)
 - 9.1 Europe Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Valves
 - 9.1.2.1 Tissue Valve
 - 9.1.2.2 Transcatheter Valve
 - 9.1.2.3 Mechanical Valve
 - 9.1.2.4 Others
 - 9.1.3 Pacemakers
 - 9.1.3.1 Implantable Pacemakers
 - 9.1.3.2 External Pacemakers
 - 9.1.3.3 Others
 - 9.2 Europe Cardiac Prosthetic Devices Market (2018-2034) by End User
 - 9.2.1 Market Overview
 - 9.2.2 Hospitals & Clinics
 - 9.2.3 Ambulatory Surgical Centers (ASCs)
 - 9.2.4 Others
 - 9.3 Europe Cardiac Prosthetic Devices Market (2018-2034) by Country
 - 9.3.1 United Kingdom
 - 9.3.1.1 United Kingdom Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 9.3.2 Germany
 - 9.3.2.1 Germany Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 9.3.3 France
 - 9.3.3.1 France Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 9.3.4 Italy
 - 9.3.4.1 Italy Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 9.3.5 Others
- 10 Asia Pacific Cardiac Prosthetic Devices Market (218-2034)
 - 10.1 Asia Pacific Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.1.1 Market Overview
 - 10.1.2 Valves
 - 10.1.2.1 Tissue Valve
 - 10.1.2.2 Transcatheter Valve
 - 10.1.2.3 Mechanical Valve
 - 10.1.2.4 Others
 - 10.1.3 Pacemakers
 - 10.1.3.1 Implantable Pacemakers
 - 10.1.3.2 External Pacemakers
 - 10.1.3.3 Others
 - 10.2 Asia Pacific Cardiac Prosthetic Devices Market (2018-2034) by End User
 - 10.2.1 Market Overview
 - 10.2.2 Hospitals & Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.3 Ambulatory Surgical Centers (ASCs)
- 10.2.4 Others
- 10.3 Asia Pacific Cardiac Prosthetic Devices Market (2018-2034) by Country
 - 10.3.1 China
 - 10.3.1.1 China Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.3.2 Japan
 - 10.3.2.1 Japan Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.3.3 India
 - 10.3.3.1 India Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.3.4 ASEAN
 - 10.3.4.1 ASEAN Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.3.5 Australia
 - 10.3.5.1 Australia Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 10.3.6 Others
- 11 Latin America Cardiac Prosthetic Devices Market (218-2034)
 - 11.1 Latin America Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 11.1.1 Market Overview
 - 11.1.2 Valves
 - 11.1.2.1 Tissue Valve
 - 11.1.2.2 Transcatheter Valve
 - 11.1.2.3 Mechanical Valve
 - 11.1.2.4 Others
 - 11.1.3 Pacemakers
 - 11.1.3.1 Implantable Pacemakers
 - 11.1.3.2 External Pacemakers
 - 11.1.3.3 Others
 - 11.2 Latin America Cardiac Prosthetic Devices Market (2018-2034) by End User
 - 11.2.1 Market Overview
 - 11.2.2 Hospitals & Clinics
 - 11.2.3 Ambulatory Surgical Centers (ASCs)
 - 11.2.4 Others
 - 11.3 Latin America Cardiac Prosthetic Devices Market (2018-2034) by Country
 - 11.3.1 Brazil
 - 11.3.1.1 Brazil Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 11.3.2 Argentina
 - 11.3.2.1 Argentina Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 11.3.3 Mexico
 - 11.3.3.1 Mexico Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 11.3.4 Others
- 12 Middle East and Africa Cardiac Prosthetic Devices Market (218-2034)
 - 12.1 Middle East and Africa Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 12.1.1 Market Overview
 - 12.1.2 Valves
 - 12.1.2.1 Tissue Valve
 - 12.1.2.2 Transcatheter Valve
 - 12.1.2.3 Mechanical Valve
 - 12.1.2.4 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.3 Pacemakers
 - 12.1.3.1 Implantable Pacemakers
 - 12.1.3.2 External Pacemakers
 - 12.1.3.3 Others
- 12.2 Middle East and Africa Cardiac Prosthetic Devices Market (2018-2034) by End User
 - 12.2.1 Market Overview
 - 12.2.2 Hospitals & Clinics
 - 12.2.3 Ambulatory Surgical Centers (ASCs)
 - 12.2.4 Others
- 12.3 Middle East and Africa Cardiac Prosthetic Devices Market (2018-2034) by Country
 - 12.3.1 Saudi Arabia
 - 12.3.1.1 Saudi Arabia Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 12.3.2 United Arab Emirates
 - 12.3.2.1 United Arab Emirates Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 12.3.3 Nigeria
 - 12.3.3.1 Nigeria Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 12.3.4 South Africa
 - 12.3.4.1 South Africa Cardiac Prosthetic Devices Market (2018-2034) by Product Type
 - 12.3.5 Others
- 13 Regulatory Framework
 - 13.1 Regulatory Overview
 - 13.2 US FDA
 - 13.3 EU EMA
 - 13.4 INDIA CDSCO
 - 13.5 JAPAN PMDA
 - 13.6 Others
- 14 Patent Analysis
 - 14.1 Analysis by Type of Patent
 - 14.2 Analysis by Publication Year
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Patent Age
 - 14.5 Analysis by CPC Analysis
 - 14.6 Analysis by Patent Valuation
 - 14.7 Analysis by Key Players
- 15 Funding and Investment Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Strategic Initiatives
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Initiatives
 - 16.3 Analysis by Joint Ventures
 - 16.4 Analysis by Leading Players
 - 16.5 Analysis by Geography

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17 Supplier Landscape
 - 17.1 Market Share Analysis, By Region (Top 5 Companies)
 - 17.1.1 Market Share Analysis: Global
 - 17.1.2 Market Share Analysis: North America
 - 17.1.3 Market Share Analysis: Europe
 - 17.1.4 Market Share Analysis: Asia Pacific
 - 17.1.5 Market Share Analysis: Others
 - 17.2 Abbott
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Company News and Development
 - 17.2.5 Certifications
 - 17.3 Medtronic plc
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Company News and Development
 - 17.3.5 Certifications
 - 17.4 Boston Scientific Corporation
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Company News and Development
 - 17.4.5 Certifications
 - 17.5 Edwards Lifesciences Corporation
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Company News and Development
 - 17.5.5 Certifications
 - 17.6 Biotronik
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Company News and Development
 - 17.6.5 Certifications
 - 17.7 Lepu Medical Technology Co. Ltd.
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Company News and Development
 - 17.7.5 Certifications
 - 17.8 Meril Life Sciences Pvt. Ltd.
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.8.4 Company News and Development

17.8.5 Certifications

18 Global Cardiac Prosthetic Devices Market - Distribution Model (Additional Insight)

18.1 Overview

18.2 Potential Distributors

18.3 Key Parameters for Distribution Partner Assessment

19 Key Opinion Leaders (KOL) Insights (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiac Prosthetic Devices Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 400 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com